CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting this summer. Coverage brought to you by

CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs. Coverage brought to you by

Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis. Coverage brought to you by

CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile. Coverage brought to you by

Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.

CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.

CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.

Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.

CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.

Biotech veteran James Bianco, discusses his new Tampa based company, which is already in a trial designed to read out for potentially both accelerated and full approval. Coverage brought to you by

She covers KRAS, ROS1, EGFR, and more. Coverage brought to you by

CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September. Coverage brought to you by

CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients. Coverage brought to you by

CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week. Coverage brought to you by

He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a €38 series C. Coverage brought to you by

CEO Jordi Fàbrega and CSO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta. Coverage brought to you by

CEO Jean Marie Duvall describes the company's programs, one focused on male infertility and another that may have dual purposes of helping with embryo implantation and adenomyosis. She says to make sure there is a clear commercial path if when you focus on this field. Coverage brought to you by:

CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development. Coverage brought to you by:

CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year. Coverage brought to you by: